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matched case–control clinical research study:
advantages, disadvantages and methodological
considerations
Emilie K Johnson1,2*, Sarabeth Broder-Fingert3, Pornthep Tanpowpong4, Jonathan Bickel5,6, Jenifer R Lightdale7
and Caleb P Nelson1Abstract
Background: A major aim of the i2b2 (informatics for integrating biology and the bedside) clinical data informatics
framework aims to create an efficient structure within which patients can be identified for clinical and translational
research projects.
Our objective was to describe the respective roles of the i2b2 research query tool and the electronic medical
record (EMR) in conducting a case-controlled clinical study at our institution.
Methods: We analyzed the process of using i2b2 and the EMR together to generate a complete research database
for a case–control study that sought to examine risk factors for kidney stones among gastrostomy tube (G-tube) fed
children.
Results: Our final case cohort consisted of 41/177 (23%) of potential cases initially identified by i2b2, who were
matched with 80/486 (17%) of potential controls. Cases were 10 times more likely to be excluded for inaccurate
coding regarding stones vs. inaccurate coding regarding G-tubes. A majority (67%) of cases were excluded due to
not meeting clinical inclusion criteria, whereas a majority of control exclusions (72%) occurred due to inadequate
clinical data necessary for study completion. Full dataset assembly required complementary information from i2b2
and the EMR.
Conclusions: i2b2 was critical as a query analysis tool for patient identification in our case–control study. Patient
identification via procedural coding appeared more accurate compared with diagnosis coding. Completion of our
investigation required iterative interplay of i2b2 and the EMR to assemble the study cohort.
Keywords: Case–control studies, Methodology, Administrative data, InformaticsBackground
The i2b2 (informatics for integrating biology and the
bedside) clinical data informatics framework was origin-
ally developed within the Partners Healthcare System, a
large, integrated healthcare system based in Boston [1].
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1Department of Urology, Boston Children’s Hospital, 300 Longwood Ave, HU
3rd Floor, Boston, MA 02115, USA
2Harvard-Wide Pediatric Health Services Research Fellowship, Boston, MA,
USA
Full list of author information is available at the end of the article
© 2014 Johnson et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orin 2007 with support from an NIH-funded National Center
for Biomedical Computing [2]. Since its inception, over 200
scholarly articles have been published using data derived
from i2b2 systems [3]. A major aim of i2b2 is to create a
cost-effective and efficient way to identify patients for many
types of clinical and translational research [1].
At Boston Children’s Hospital (BCH), the data con-
tained within i2b2 is obtained from multiple administra-
tive and electronic medical record data sources, including
hospital and physician billing records and data generated
over the course of clinical care. Specific available data types
include demographics, medications, laboratory values, andl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Modification (ICD-9-CM) billing and procedure codes. The
clinical and administrative data sources feed into i2b2 to
provide a searchable composite data repository that is used
by clinical and translational researchers at our hospital.
Clinical data becomes available to i2b2 as it becomes digi-
tized, such that laboratory data is robust going back many
years, whereas detailed prescription data has become more
universally available as more providers have begun to use
electronic, rather than paper, prescriptions. Therefore, avail-
ability of specific clinical data elements through i2b2 is
largely time-dependent.
Our group at BCH recently used the i2b2’s ontological
search framework to conduct a case–control study exam-
ining risk factors for the development of kidney stones
among pediatric patients cared for at our institution who
are fed via gastrostomy tube (G-tube) [4]. In order to as-
semble the database for this study, we undertook a multi-
step process that required:
1. Access to the patient population of interest
2. Accurate identification of cases based on pre-
specified inclusion and exclusion criteria
3. Assurance that cases arose from the same
population from which we were drawing our
matched controls
4. Case–control matching based on pre-specified
matching criteria.
The objectives of this paper are to evaluate the role of
i2b2 in creating the dataset for our case–control study,
and to discuss the interplay between this research query
tool and clinical data extracted through detailed chart re-
view. In particular, we describe the utility of i2b2 for iden-
tifying cases and controls at a single institution, from our
perspective as clinical investigators.
Methods
A schematic of our data collection strategy is illustrated
in Figure 1.
Potential cases (defined as patients with both G-tubes
and kidney stones) were identified via an i2b2 query that
requested the presence of at least 1 ICD-9-CM or Current
Procedural Terminology (CPT) code for a G-tube (ICD-
9-CM codes v44.1, 43.19, 43.11, 43.19, v55.1, 96.36, 97.02,
536.40, 536.41, 536.42, and 536.49; CPT codes 43246,
43653, 43750, 43760, 43830, 43831, 43832, 49440, 49450,
49465, and 74350) and at least 1 ICD-9-CM code repre-
senting a kidney stone (592.1, 592.2, 592.9). The initial
query was conducted through the i2b2 workbench by our
clinical research team, which produced a de-identified
dataset. After IRB approval, the query was processed by
the i2b2 Clinical Research Informatics Team, which
allowed identification of potential cases.The medical records of potential cases were then
reviewed by the clinical research team to confirm eligibil-
ity for the study. Criteria for inclusion in the study were 1)
an incident stone diagnosis between January 2005 and
December 2011 and 2) a patient age of 1–21 at the time of
stone diagnosis. Cases were excluded if 1) the presence of
a G-tube or kidney stone could not be verified from within
the clinical chart, 2) the kidney stone history predated
G-tube placement, 3) there was insufficient data regarding
tube feed formulation and/or regimen, or 4) the patient
had received G-tube feeds for less than 3 months in the 12
months prior to the date of the kidney stone diagnosis.
Cases were also later excluded if at least 1 eligible control
could not be identified.
The final list of cases was then cross-referenced with
patients identified via i2b2 as having one or more of the
G-tube ICD-9-CM or CPT codes detailed above, in the
absence of an ICD-9-CM code for a kidney stone, to iden-
tify potential controls. Criteria were then applied by the
automated i2b2 system to match all potential control
patients to the existing case list based on date of birth
(±1 year) and gender.
The list of all potential controls was then sorted ran-
domly by case number and sequentially examined via
chart review until 2 controls were identified for each case.
In addition to age and gender matching, each control was
also matched to each case based on timing of G-tube
placement. Specifically, to be eligible for the study, each
control was required to have had a G-tube in place and to
have been receiving tube feeds during at least 3 out of the
12 months prior to the date of kidney stone diagnosis for
their matched case. Potential controls that did not meet
these criteria were excluded, as were those in which the
presence of a G-tube could not be verified or the nutri-
tional data contained within their chart was deemed insuf-
ficient for the purposes of our study.
The reasons for exclusion of patients from the study
cohort after initial inclusion via the i2b2 search algorithm
were tabulated and categorized for both cases and con-
trols. The study from which these data were derived was
reviewed and approved by the Boston Children’s Hospital
Institutional Review Board (Protocol # IRB-P000029420).
Results
The initial i2b2 query identified 177 potentially eligible
cases as having both an ICD-9-CM and/or CPT code for a
G-tube and an ICD-9 code for a kidney stone. We ex-
cluded 136 cases due to aforementioned reasons (Figure 2).
The final case cohort consisted of 41 cases (23.2% of the
potential cases initially identified).
All identified cases (n = 41) were matched with 80
controls, who collectively represented 16.5% (80/486) of
potential controls. All identified controls had both an ICD-
9-CM and/or CPT code for a G-tube and fulfilled the
Figure 1 Strategy for assembly of case–control cohort – attached file.
Johnson et al. BMC Medical Research Methodology 2014, 14:16 Page 3 of 6
http://www.biomedcentral.com/1471-2288/14/16matching criteria for at least one of the cases. There were 2
case patients with only 1 matching control and 1 potential
case was excluded based on no eligible control. The mean
number of potential control medical records reviewed in
sequential order until a match for each case was identified
was 9.9 +/− 8.4.
A comparison of the reasons for excluding cases vs. con-
trols in the final analysis is illustrated in detail in Table 1.
Among potential cases, 22.8% were excluded based on ap-
parent inaccuracy of administrative codes, whereas this
was true for only 7.6% of potential controls. Cases were 10
times more likely to be excluded for an inaccurate kidney
stone code versus an inaccurate G-tube code. The major-
ity of control exclusions (72.2%) occurred due to inad-
equate clinical (nutritional) data to complete our study.
Discussion
In our study, i2b2 was critical as a research query tool for
screening potential cases and controls as well as for con-
ducting the matching query for our study. The full assem-
bly of our case–control cohort required an iterative
approach with multiple points of comparison between i2b2
and the clinical patient records. Approximately 23% of pa-
tients identified as eligible for our study based on the initiali2b2 query were eventually included as cases, and an aver-
age of 10 controls per case had to undergo chart review in
order to attain a 2:1 match. Among potential cases that
were ultimately excluded after chart review, 67% were ex-
cluded for not meeting our study inclusion criteria and
23% for the inability to verify the diagnosis of a stone or
presence of a G-tube on an individual patient basis. In con-
trast, potential controls were more likely to be excluded for
inadequate clinical data (72%), while coding inaccuracies
were more rare (23% of potential cases vs. 8% of potential
controls).
Throughout its design and implementation, we were
acutely aware of potential methodological pitfalls to our
case–control study [5,6]. Common limitations inherent
to a case–control study design that applied to our inves-
tigation included 1) the need to explicitly define and
apply the criteria for diagnosis of a case, 2) assurance
that cases selected were incident cases, and 3) certainty
that controls selected came from the same population
as our cases [6]. However, given a paucity of prior inves-
tigations into both our primary study question, as well
as our patient population of interest, we felt a case–
control study design to be a reasonable first step. As such,
we sought to be as standardized and comprehensive as
Figure 2 Detailed exclusions for case cohort (N = 41) – attached file.
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ing with the cohort assembly.
Previous investigators have described the use of other
databases sourced from billing/administrative tasks for
conducting case–control studies. The proportion and
magnitude of chart review necessary for each study ap-
pears to vary based on the specific diagnoses/conditions of
interest for each investigation. In a manner similar to our
use of i2b2, de Abajo and colleagues used a primary care
research database to identify patients with a condition of
interest based on administrative coding, and then con-
ducted chart review based on the initial query [7]. In their
study, the investigators initially identified cases with a
diagnosis of upper gastrointestinal (UGI) bleed based on
International Classification of Primary Care Code or free
text related to UGI bleed, which was screened via natural
language processing. Of the potential cases initially identi-
fied, 21% were included in the final case cohort after de-
tailed chart review, similar to our final case inclusion rate
of 23%. In a British case–control study examining whether
routine primary care data could be used to identify chil-
dren at risk of entering public care, Simkiss and colleagues
were able to conduct both cohort assembly and data ana-
lysis without the use of detailed chart review [8]. The
investigators did selectively validate the case selectionTable 1 Reasons for exclusion of potential study participants
Reason for exclusion Excluded potential
Inaccurate query
No kidney stone 28 (20
No G-tube 3 (2.2
Did not meet inclusion criteria
Outside of study age range 42 (30
Outside of study time period 35 (25
Kidney stone/G-tube asynchronous 14 (10
Inadequate clinical data 13 (9
Other
No matching control 1 (0.7strategy using clinician questionnaires. They were able to
confirm case status in 93%, suggesting that an automated
case selection algorithm for their condition of interest
(placement of a child into public care) was a reasonable
strategy. However, our experience and that of de Abajo
and colleagues suggest that a completely automated case
selection strategy is unlikely to yield accurate results, and
in turn may require chart review to refine study cohorts.
One alternative to using a multi-source research data-
base to facilitate the completion of institutional or
multi-institutional case–control studies is the use of a
registry-based strategy. Recent, expanded applications of
data registries harness the benefits of open data sharing
and advanced query and analytic tools in a similar fashion
to the i2b2 framework. In one instance, the International
Collaborative Gaucher Group Registry was able to estab-
lish a large, multi-institutional registry for a rare medical
condition [9]. In this project, researchers and clinicians
collaborated and agreed to enter specified data points on
for each patient on a prospective basis, which then allowed
for stratification of patients by several relevant clinical and
demographic factors, which in turn facilitated investiga-
tion of risk factors for primary outcomes, such as avascu-
lar necrosis, in this rare-disease population. Such an
approach is attractive for a variety of specific conditions.– cases vs. controls
cases (N = 136) Excluded potential controls (N = 406)
.6) NA
) 31 (7.6)
.9) NA
.7) NA
.3) 82 (20.2)
.6) 293 (72.2)
3) NA
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groups to develop registries for every possible interesting
combination of conditions (e.g. G-tube feeding plus kidney
stone). Nevertheless, this illustration of using a centralized
registry does argue for having complete lists of patients
with particular conditions whenever feasible.
Certainly, an important consideration in using a research
query tool that draws data from administrative billing
records to conduct a case–control study is the potential to
encounter inaccuracies in procedural and medical diagnos-
tic coding key to identifying particular patient populations.
In the clinical setting, several studies in prevalent diseases
have used ICD-9-CM for case identification [10-13]. How-
ever, relying on ICD-9-CM codes alone may result in bias
and disease misclassification. Recent studies have also sup-
ported the combined use of medical record review with an
administrative database to validate the diagnosis [14,15].
For example, the use of both procedural (i.e., upper gastro-
intestinal endoscopy) and diagnostic (i.e., celiac disease)
codes can improve the precision of case identification, as
compared to the use of a diagnostic code alone [10]. Over-
all, procedural codes may have higher sensitivity and
specificity compared with diagnosis codes [16,17]. In our
investigation, cases were 10 times more likely to be
excluded for an inaccurate kidney stone code versus an
inaccurate gastrostomy tube code, likely reflecting that fact
that our G-tube definitions used a combination of diagnos-
tic and procedural codes, while the kidney stone definition
relied on diagnostic codes alone.
Although our study required manual chart review to
conform to the clinical constraints of our inclusion cri-
teria, the i2b2 framework provided multiple important
advantages that warrant mention. Most simply, i2b2 has
both ICD-9-CM and CPT coding available for query, a fea-
ture that is not universal in administrative data sources. A
specific advantage of i2b2 compared with traditional bill-
ing data is the ability to cross-reference several billing
codes to generate a list of unique patients with multiple
conditions of interest. i2b2 also contains an intuitive user
interface that allows blinded (de-identified) screening
queries to be conducted by the clinical research team
based on ICD-9-CM and/or CPT coding. This feature
allows clinical researchers to assess study feasibility prior
to initiating a complete investigational protocol, or to
obtaining formal IRB approval. Additional functionality of
i2b2 included its ability to specify matched case–control
groups based on predetermined criteria; in turn, i2b2
provided a critical means for our cases and controls to
be selected from the same source population. Finally,
i2b2 contains clinical data including laboratory results
and biometric measurements, which could all be
extracted into our dataset in a substantially streamlined,
reliable fashion when compared with the alternative of
manual chart abstraction.At its current level of functionality, i2b2 did have several
limitations. For instance, we were unable to comprehen-
sively query clinical data beyond diagnosis and procedural
coding. Even with the recent incorporation of natural lan-
guage processing into i2b2, [18] it is difficult to imagine
that the entire case–control cohort assembly process
could be completed automatically without significant
restructuring of the format of clinical data inputs. In the
absence of clinical data restructuring, we could have
potentially improved our initial query strategy by applying
a more specific initial filter that included dates of service
and/or by requiring particular encounter types. As an
example, the majority of nutrition data were contained
within certain visit types, so we could have required that a
patient have a GI, complex care, nutrition or inpatient en-
counter to be eligible for further screening. We also con-
sidered limiting age ranges during the initial query so that
fewer patients would be excluded due to being outside of
the age range for our study. However, we were concerned
that we could have missed potential cases or controls with
more specific initial filters, so we elected to be broader in
our search strategy for this index study using the i2b2
framework for case-cohort assembly.Conclusions
In summary, the i2b2 multi-source data informatics
framework was critical as a query analysis tool for patient
identification in our case–control study examining risk
factors for kidney stones among G-tube fed children. Pa-
tient identification via procedural and diagnostic coding
appeared more accurate compared with diagnostic coding
alone. i2b2 also streamlined multiple additional aspects of
our investigation, including the assessment of feasibility,
case–control matching, and clinical data abstraction. Full
completion of our study required an iterative interplay
between administrative data and the more granular clin-
ical record. Nevertheless, i2b2 remained a critical compo-
nent at multiple steps in our study execution. Moving
forward, enhancements such as natural language process-
ing will continue to improve the i2b2 framework as a tool
for clinical researchers, and will further distinguish this as
a tool for generating clinical research datasets as com-
pared with standard administrative data sources. In turn,
we anticipate that its utility to case–control studies and
other types of clinical investigations will continue to grow.Consent
This study was conducted as part of an investigation that
was approved by the Institutional Review Board at Boston
Children's Hospital. The study was reviewed and deter-
mined to be exempt from individual patient consent due
to its retrospective nature.
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